Xiaoyong Dai

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Inflammatory Response

Basal Cell Carcinoma

Endoplasmic Reticulum Stress

Top Venues

Journal of experimental & clinical cancer research : CR

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

This page only lists publications with an associated author ORCID identifier.

Publications

Chunyan Feng, Albert Yu, Zhongfu Wang, Kun Wang, Jiawei Chen, Yaojiong Wu, Ting Deng, Huaqing Chen, Yibo Hou, Shaohua Ma, Xiaoyong Dai, Laiqiang Huang
A novel PDPN antagonist peptide CY12-RP2 inhibits melanoma growth via Wnt/β-catenin and modulates the immune cells. Journal of experimental & clinical cancer research : CR 43 (1) (2024)
Chunyan Feng, Albert Yu, Zhongfu Wang, Kun Wang, Jiawei Chen, Yaojiong Wu, Ting Deng, Huaqing Chen, Yibo Hou, Shaohua Ma, Xiaoyong Dai, Laiqiang Huang
A novel PDPN antagonist peptide CY12-RP2 inhibits melanoma growth via Wnt/β-catenin and modulates the immune cells. Journal of experimental & clinical cancer research : CR 43 (1) (2024)
Chunyan Feng, Albert Yu, Zhongfu Wang, Kun Wang, Jiawei Chen, Yaojiong Wu, Ting Deng, Huaqing Chen, Yibo Hou, Shaohua Ma, Xiaoyong Dai, Laiqiang Huang
A novel PDPN antagonist peptide CY12-RP2 inhibits melanoma growth via Wnt/β-catenin and modulates the immune cells. Journal of experimental & clinical cancer research : CR 43 (1) (2024)
Kun Wang, Albert Yu, Kewei Liu, Chunyan Feng, Yibo Hou, Jiawei Chen, Shaohua Ma, Laiqiang Huang, Xiaoyong Dai
Nano-LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec-10 Signaling Pathway. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023)